CRCarla Rowe

Carla Rowe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Carla Rowe has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Andrew A. Udy

    Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine Monash University Melbourne Victoria Australia

    3 shared publications
  • Bridget Little

    Starship Child Health Auckland City Hospital Auckland New Zealand

    3 shared publications
  • Emma Jean Ridley

    Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia; Dietetics and Nutrition Department, Alfred Health, Melbourne, Victoria, Australia

    3 shared publications
  • Jacinta Winderlich

    Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine Monash University Melbourne Victoria Australia

    3 shared publications
  • Jemma Woodgate

    Department of Dietetics & Food Services Queensland Children's Hospital Brisbane Queensland Australia

    3 shared publications
  • Kirsten Sim

    Nutrition and Dietetics The Children's Hospital at Westmead Westmead New South Wales Australia

    3 shared publications

Latest Publications

  • Open Access

    Pancreatic, nutritional and clinical outcomes in children 0–5 years with cystic fibrosis during the first 2 years of CFTR modulator therapy (PaNC): a multicentre prospective observational study protocol

    by Caitlin Miles, Tamarah Katz, Jodi Grunert, Kristyn Ford, Carla Hall, Charlotte Hawthorn, Denise Wong See, Mylie McMahon, Hannah Vass, Sarah Watkins, et al.

    Background Cystic fibrosis (CF) is a genetic condition of impaired membrane electrolyte transport and is characterised by defects in the production and function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Ground-breaking CFTR modulator therapy has resulted in a notable shift in the clinical presentation and progressive nature of CF, across both pulmonary and extrapulmonary systems. Access to CFTR modulator therapies in people with CF is occurring in a staged, descending age process, with clinical trials focusing primarily on safety and efficacy. There is a lack of robust, real-world longitudinal data on CFTR modulator therapy in infants and young children where extrapulmonary outcomes such as growth, micronutrient status and pancreatic function are the key focus. Methods and analysis Pancreatic, nutritional and clinical outcomes in children 0–5 years with CF during the first 2 years of CFTR modulator therapy (PaNC) is a prospective cohort study involving all eight tertiary paediatric CF centres in Australia. Infants and children 4 months to 5 years of age who are eligible for elexacaftor/tezacaftor/ivacaftor (ETI) or ivacaftor (IVA) meet the inclusion criteria for PaNC, with a total eligible cohort of 303 children at the commencement of recruitment. The primary outcomes are change in weight-for-length/body mass index z score and change in serum micronutrient status, at 6–12 monthly intervals, during the first 2 years of treatment with ETI or IVA. Secondary outcomes include change in exocrine pancreatic function, measured by faecal elastase-1, change in the use and dose of pancreatic enzyme replacement therapy, nutritional and gastrointestinal therapies and change in sweat chloride levels. Linear mixed modelling will be used to analyse primary and secondary endpoints. This protocol is reported in accordance with ‘The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement’ reporting guidelines. Ethics and dissemination Overarching governance and ethics approval has been granted by Monash Health Human Research Ethics Committee, in addition to all eight sites receiving site-specific authorisation approvals prior to the commencement of recruitment. Opportunities for CF consumers to be involved in targeted dissemination plans will be initiated via CF Australia at the completion of the study period. Additionally, a summary of non-identifiable results will be provided to CF consumers and CF healthcare providers via scientific and lay conferences and via peer-reviewed journals. Trial registration number ACTRN12624001185550; Pre-results.


  • Open Access

    Characteristics of enteral and oral nutrition support among infants and young children in the pediatric intensive care unit: A descriptive cohort study

    by Jacinta Winderlich, Bridget Little, Felix Oberender, Tessa Bollard, Tamara Farrell, Samantha Jenkins, Emma Landorf, Andrea McCall, Jessica Menzies, Katie O'BRien, et al.

    Background: Children who are critically ill are often reliant on enteral and oral nutrition support. However, there is limited evidence to guide “what” to prescribe, and current practice is unknown. The primary objective of this study was to describe enteral nutrition prescription in children ≤2 years of age in the pediatric intensive care unit (PICU). The secondary objectives were to describe oral nutrition support practices and factors associated with the use of increased energy and protein density nutrition support.Methods: Children ≤2 years of age admitted to participating PICUs over a 2‐week period in June 2021 were enrolled. Data were collected on PICU admission days 1 to 7, 14, 21, and 28 on the mode of nutrition, enteral and oral nutrition support prescription, and dietitian intervention.Results: Eighty‐four children were included (49 [58%] male; 79 [94%] ≤1 year of age). Enteral nutrition was administered to 79 (94%) children (with expressed breast milk in 45 [57%]). Forty‐three children received formula as enteral nutrition. Increased energy and protein density formulas were provided to 14 (33%) children enterally, with concentrated standard infant formula powder being the most common (5 [12%]). Among children offered oral intake (22; 26%), three (14%) received oral nutrition support. Children who received increased energy and protein density enteral nutrition were more likely to receive dietitian intervention (P = 0.002).Conclusion: In children ≤2 years of age admitted to PICU, expressed breast milk was provided to half of those requiring enteral nutrition and oral nutrition support prescription was infrequent. One third of children receiving formula via enteral nutrition received an increased energy and protein density feed, and this was strongly associated with dietitian intervention.


  • Open Access

    Nutrition provision in Australian and New Zealand PICUs: A prospective observational cohort study (ePICUre)

    by Jacinta Winderlich, Bridget Little, Felix Oberender, Tessa Bollard, Tamara Farrell, Samantha Jenkins, Emma Landorf, Andrea McCall, Jessica Menzies, Katie O'BRien, et al.


  • Open Access

    Dietitian and nutrition-related practices and resources in Australian and New Zealand PICUs: A clinician survey

    by Jacinta Winderlich, Bridget Little, Felix Oberender, Tamara Farrell, Samantha Jenkins, Emma Landorf, Jessica Menzies, Katie O'Brien, Carla Rowe, Kirsten Sim, et al.